Clinical Trials Logo

High Risk of Recurrence clinical trials

View clinical trials related to High Risk of Recurrence.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06327269 Recruiting - Clinical trials for High Risk of Recurrence

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

Start date: April 1, 2021
Phase: Early Phase 1
Study type: Interventional

The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these patients. Using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. It can be used to get a better treatment response and tumor necrosis before LDLT. As a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. In addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. A new generation of targeted therapies will be applied to adjuvant therapy after LDLT.

NCT ID: NCT05602415 Recruiting - Soft Tissue Sarcoma Clinical Trials

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Start date: November 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma